You have 9 free searches left this month | for more free features.

PI3K inhibitor

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)

Recruiting
  • Follicular Lymphoma
  • München, Bavaria, Germany
  • +39 more
May 19, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin Trial in United States (duvelisib, PI3K inhibitor)

Terminated
  • Lymphoma, Small Lymphocytic
  • +4 more
  • Little Rock, Arkansas
  • +10 more
Mar 15, 2021

Colorectal Cancer, Gastric Cancer, HER2-negative Breast Cancer Trial (TOS-358)

Not yet recruiting
  • Colorectal Cancer
  • +8 more
  • (no location specified)
Jan 5, 2023

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

Terminated
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022

HNSCC Trial in Houston (Bimiralisib)

Terminated
  • HNSCC
  • Houston, Texas
    M.D. Anderson Cancer Center
Dec 22, 2021

Stomach Tumors Esophageal Tumors Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein Trial in Worldwide

Completed
  • Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
  • Boston, Massachusetts
  • +8 more
Dec 6, 2020

Head and Neck Squamous Cell Carcinoma Trial (TL117, Paclitaxel)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Apr 9, 2021

Breast Cancer Trial in Spain, United States (BKM120)

Completed
  • Breast Cancer
  • Boston, Massachusetts
  • +6 more
Oct 6, 2020

Mixed Tumor, Malignant Trial in United States (BAY806946)

Recruiting
  • Mixed Tumor, Malignant
  • Birmingham, Alabama
  • +20 more
Jan 20, 2023

Asthma Trial in Germany, United Kingdom (IPI-145, a PI3K Inhibitor, Placebo to match IPI-145)

Completed
  • Asthma
  • IPI-145, a PI3K Inhibitor
  • Placebo to match IPI-145
  • Berlin, Germany
  • +3 more
Mar 15, 2021

Carcinoma, Squamous Cell of Head and Neck Trial in France (Copanlisib, Cetuximab)

Terminated
  • Carcinoma, Squamous Cell of Head and Neck
  • Angers, France
  • +6 more
Mar 24, 2021

Advanced Gastric Adenocarcinoma Trial in Seoul (GSK2636771, Paclitaxel)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System, Yonsei Canc
Apr 21, 2021

Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Copanlisib (Aliqopa, BAY80-6946)
  • Birmingham, Alabama
  • +100 more
Feb 10, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Los Angeles, California
  • +4 more
Jul 19, 2022

Breast Cancer Trial in Los Angeles, Bronx (Gedatolisib, Faslodex, Palbociclib)

Active, not recruiting
  • Breast Cancer
  • Los Angeles, California
  • +1 more
Jan 25, 2022

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

Glioblastoma, Adult Trial in United States (Paxalisib (GDC-0084))

Active, not recruiting
  • Glioblastoma, Adult
  • Paxalisib (GDC-0084)
  • Los Angeles, California
  • +5 more
Aug 16, 2022

Lymphoma, T-Cell Trial (Copanlisib, Romidepsin)

Withdrawn
  • Lymphoma, T-Cell
  • (no location specified)
Aug 11, 2020

Metastatic Colorectal Cancer Trial in Worldwide (MEN1611, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • Phoenix, Arizona
  • +26 more
Feb 14, 2022

Advanced or Metastatic Breast Cancer Trial in Worldwide (MEN1611, Trastuzumab, Fulvestrant)

Active, not recruiting
  • Advanced or Metastatic Breast Cancer
  • Fort Lauderdale, Florida
  • +26 more
Feb 14, 2022